Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

- PMLiVE

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Garraway joins from Eli Lilly

Roche Basel Switzerland

Roche undercuts price of Bayer cancer drug after winning FDA approval

Both drugs highly effective in small subset of patients

- PMLiVE

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links